$RETA (+1.9% pre) Reata Pharma (RETA) Reports Reacquisition of Rights From AbbVie $ABBV to Develop &amp; Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators - SI

http://ooc.bz/l/42781
<ticker> + <number> % pre reata pharma <ticker> reports reacquisition of rights from <company> <ticker> to develop & commercialize bardoxolone  methyl , omaveloxolone  , and all next - generation nrf <number> activators - si